OmniLytics Enters Collaboration With Elanco

Salt Lake City UT - OmniLytics, Inc. of Salt Lake City, UT recently announced that it has entered into a collaborative research and license agreement with Elanco, a division of Eli Lilly and Company, encompassing a series of products for the treatment of food-borne bacterial pathogens using OmniLytics' bacteriophage ("phage") technology.

The companies will focus on phage-based products that could help the animal health and food production industries in their struggle to control outbreaks of human pathogenic bacteria such as E. coli, Salmonella and Listeria, and the numerous cases of human illness associated with them.

Justin Reber, President & CEO of OmniLytics, stated, "We're thrilled with the commitment by Elanco to actively pursue solutions in a market that is so critical to the consumers of the world. They share OmniLytics' vision to reduce the threat of contamination in the food chain associated with these pathogens. The synergies gained through our combined resources have created an exciting partnership by combining the phage expertise of OmniLytics with the product development, market understanding, sales channel, brand and reach of Elanco."

The commercial use of phage products to control bacteria on foods is not a new concept. OmniLytics has been successfully treating crops in the United States with their AgriPhage product line for more than a decade. Phages provide an effective, natural alternative to broad spectrum antibiotics and other chemicals in the fight against bacterial disease and contamination.

SOURCE: OmniLytics, Inc.